Drug Information

Drug General Information
Drug ID
D0VT0T
Former ID
DIB013066
Drug Name
NLX-P101
Synonyms
RAAV-GAD; STN AAV-GAD gene therapy, Neurologix; Subthalamic nucleus AAV-glutamic acid decarboxylase gene therapy, Neurologix; NLX gene therapy (Parkinson's), Neurologix
Indication Parkinson's disease [ICD9: 332; ICD10:G20] Discontinued in Phase 2 [547621]
Company
Neurologix Inc
Target and Pathway
Target(s) Glutamate decarboxylase Target Info Modulator [530985]
BioCyc Pathway Glutamate dependent acid resistance
GABA shunt
Glutamine biosynthesis
KEGG Pathway Alanine, aspartate and glutamate metabolism
Arginine and proline metabolism
Glyoxylate and dicarboxylate metabolism
Nitrogen metabolism
Metabolic pathways
Biosynthesis of amino acids
Glutamatergic synapse
GABAergic synapse
PANTHER Pathway Glutamine glutamate conversion
Reactome Amino acid synthesis and interconversion (transamination)
WikiPathways Metabolism of amino acids and derivatives
TNF alpha Signaling Pathway
Neurotransmitter uptake and Metabolism In Glial Cells
References
Ref 547621Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017938)
Ref 530985NLX-P101, an adeno-associated virus gene therapy encoding glutamic acid decarboxylase, for the potential treatment of Parkinson's disease. Curr Opin Investig Drugs. 2010 Jul;11(7):813-22.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.